PDS Biotechnology (EU6) Ratios
PDS Biotechnology Ratios
DE:EU6's free cash flow for Q2 2026 was $-2.79M. For the 2026 fiscal year, DE:EU6's free cash flow was increased by $0.00 and operating cash flow was $-2.79M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Mar 22 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 2.98 | 2.64 | 4.33 | 7.79 | 17.80 |
| Quick Ratio | 2.98 | 2.64 | 4.33 | 7.79 | 17.80 |
| Cash Ratio | 2.82 | 2.44 | 4.15 | 7.52 | 17.37 |
| Solvency Ratio | -1.62 | -1.42 | -1.29 | -1.24 | -4.24 |
| Operating Cash Flow Ratio | -2.93 | -2.05 | -2.47 | -2.62 | -3.32 |
| Short-Term Operating Cash Flow Coverage | -5.41 | -2.80 | -8.07 | 0.00 | 0.00 |
| Net Current Asset Value | $ 7.01M | $ 18.70M | $ 25.80M | $ 43.47M | $ 62.85M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.56 | 0.48 | 0.40 | 0.30 | 0.01 |
| Debt-to-Equity Ratio | 1.83 | 1.15 | 0.91 | 0.53 | 0.01 |
| Debt-to-Capital Ratio | 0.65 | 0.53 | 0.48 | 0.35 | 0.01 |
| Long-Term Debt-to-Capital Ratio | 0.56 | 0.33 | 0.43 | 0.34 | 0.00 |
| Financial Leverage Ratio | 3.30 | 2.39 | 2.27 | 1.75 | 1.06 |
| Debt Service Coverage Ratio | -2.78 | -1.91 | -4.62 | -30.02 | 0.00 |
| Interest Coverage Ratio | -5.91 | -7.77 | -10.23 | -31.64 | 0.00 |
| Debt to Market Cap | 0.47 | 0.37 | 0.15 | 0.06 | 0.00 |
| Interest Debt Per Share | 0.48 | 0.73 | 0.91 | 0.87 | 0.02 |
| Net Debt to EBITDA | 0.32 | 0.59 | 0.82 | 1.24 | 3.02 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 96.72% | 97.74% | 96.83% | 97.15% | 78.93% |
| EBT Per EBIT | 113.07% | 105.94% | 103.03% | 100.92% | 99.98% |
| Return on Assets (ROA) | -113.12% | -82.92% | -72.31% | -53.05% | -25.18% |
| Return on Equity (ROE) | -372.85% | -197.90% | -164.33% | -92.85% | -26.77% |
| Return on Capital Employed (ROCE) | -150.13% | -128.47% | -94.07% | -62.02% | -33.79% |
| Return on Invested Capital (ROIC) | -116.55% | -86.94% | -83.39% | -60.00% | -26.56% |
| Return on Tangible Assets | -113.12% | -82.92% | -72.31% | -53.05% | -25.18% |
| Earnings Yield | -96.61% | -63.30% | -27.91% | -10.82% | -8.16% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.04 | 0.01 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -10285.44 | -44460.29 | 0.00 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 10285.44 | 44460.29 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.60 | -0.96 | -1.09 | -0.90 | -0.49 |
| Free Cash Flow Per Share | -0.60 | -0.96 | -1.09 | -0.90 | -0.49 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | -1207.94 | 0.00 | 0.00 | 0.00 |
| Capital Expenditure Coverage Ratio | 0.00 | -1207.94 | 0.00 | 0.00 | 0.00 |
| Operating Cash Flow Coverage Ratio | -1.64 | -1.60 | -1.41 | -1.10 | -25.46 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -77.72% | -59.00% | -21.87% | -6.81% | -6.02% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -1.04 | -1.58 | -3.58 | -9.24 | -12.25 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 3.86 | 3.13 | 5.89 | 8.58 | 3.28 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -1.29 | -1.69 | -4.57 | -14.68 | -16.61 |
| Price-to-Operating Cash Flow Ratio | -1.29 | -1.70 | -4.57 | -14.68 | -16.61 |
| Price-to-Earnings Growth (PEG) Ratio | 0.04 | 0.06 | 1.28 | -0.08 | 0.47 |
| Enterprise Value Multiple | -0.86 | -1.17 | -3.02 | -8.03 | -6.65 |
| Enterprise Value | 25.92M | 39.56M | 121.12M | 327.16M | 142.58M |
| EV to EBITDA | -0.86 | -1.17 | -3.02 | -8.03 | -6.65 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -0.93 | -1.13 | -3.60 | -12.73 | -11.42 |
| EV to Operating Cash Flow | -0.93 | -1.13 | -3.60 | -12.73 | -11.42 |
| Tangible Book Value Per Share | 0.20 | 0.52 | 0.84 | 1.54 | 2.47 |
| Shareholders’ Equity Per Share | 0.20 | 0.52 | 0.84 | 1.54 | 2.47 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.03 | 0.02 | 0.03 | 0.03 | 0.21 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -0.74 | -1.03 | -1.39 | -1.43 | -0.66 |
| Tax Burden | 0.97 | 0.98 | 0.97 | 0.97 | 0.79 |
| Interest Burden | 1.18 | 1.14 | 1.10 | 1.03 | 1.00 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.80 | 0.93 | 0.78 | 0.63 | 0.74 |
Currency in USD
